FDA reviews two novel ADHD drug candidates in late-stage development, offering new approaches to treatment.
Noninvasive tests now replace risky liver biopsies for diagnosing metabolic dysfunction-associated steatohepatitis (MASH) and MASLD,...
FDA approves Oveporexton (Orzeyful) for Type 1 Narcolepsy, first therapy to restore orexin signaling. Learn...
FDA Week: New blood test for Alzheimer's disease approved. See how Elecsys pTau217 helps identify...
FDA approval of Avulux migraine lenses offers an over‑the‑counter solution to reduce photophobia for migraine...
Australia cannot afford business as usual amid Northern Hemisphere fires, as global climate crises intensify....
Explore how the Murdoch empire’s media tactics impact public health, revealing key insights from the...
AI scribes raise regulatory concerns with Therapeutic Goods Administration acting against suppliers over safety issues...
AI medical training is revolutionizing doctor education as AI passes licensing exams, but experts warn...
AI threatens traditional medical education with 81% of doctors using AI in practice and education,...